Get the Stockscreener App
0.8079
0.39%
0.0031
After Hours:
.81
0.0021
+0.26%
Assertio Holdings Inc stock is traded at $0.8079, with a volume of 158.28K.
It is up +0.39% in the last 24 hours and down -8.17% over the past month.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
See More
Previous Close:
$0.8048
Open:
$0.815
24h Volume:
158.28K
Relative Volume:
0.22
Market Cap:
$77.14M
Revenue:
$169.43M
Net Income/Loss:
$-186.01M
P/E Ratio:
-0.40
EPS:
-2.02
Net Cash Flow:
$70.07M
1W Performance:
-2.13%
1M Performance:
-8.17%
6M Performance:
-35.37%
1Y Performance:
+1.30%
1-Day Range:
$0.7995
$0.8199
1-Week Range:
$0.7802
$0.8276
52-Week Range:
$0.7324
$1.798
Assertio Holdings Inc Stock (ASRT) Company Profile
Name
Assertio Holdings Inc
Sector
Phone
(224) 419-7106
Address
100 S. SAUNDERS ROAD, LAKE FOREST, IL
Compare ASRT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASRT
Assertio Holdings Inc
|
0.8079 | 77.14M | 169.43M | -186.01M | 70.07M | -2.02 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Assertio Holdings Inc Stock (ASRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Maxim Group | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| Nov-07-22 | Initiated | Lake Street | Buy |
| Nov-30-18 | Downgrade | Mizuho | Buy → Neutral |
Assertio Holdings Inc Stock (ASRT) Latest News
Short Interest in Assertio Holdings, Inc. (NASDAQ:ASRT) Decreases By 6.5% - MarketBeat
Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years - Yahoo Finance
Assertio Holdings faces Nasdaq delisting over share price rule - MSN
Assertio Holdings, Inc. (NASDAQ:ASRT) Sees Significant Decrease in Short Interest - MarketBeat
Jane Street Group LLC Sells 277,889 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) - Defense World
Geode Capital Management LLC Purchases 42,750 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) - Defense World
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Assertio Holdings Names New Chief Commercial Officer, Awards Major Stock Incentive Package - StockTitan
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois against Assertio Holdings, Inc. - AccessWire
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Up 14.1% in December - MarketBeat
Is Assertio Holdings (NASDAQ:ASRT) A Risky Investment? - Simply Wall St
Assertio appoints new independent director to board By Investing.com - Investing.com South Africa
Assertio appoints new independent director to board - Investing.com
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - The Manila Times
Assertio Holdings Taps Former Astellas President Who Led $5B Sales Growth to Join Board - StockTitan
Assertio’s (ASRT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Assertio Therapeutics shares get buy rating on clinical trial results By Investing.com - Investing.com Canada
Assertio (NASDAQ:ASRT) Receives Buy Rating from HC Wainwright - MarketBeat
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 11.5% in November - MarketBeat
Assertio reports positive Rolvedon trial results for breast cancer By Investing.com - Investing.com Australia
Assertio Announces Results of Rolvedon (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study - Marketscreener.com
Assertio reports positive Rolvedon trial results for breast cancer - Investing.com
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - The Manila Times
Assertio's Rolvedon Shows Promising Clinical Data in Breast Cancer Trial with Same-Day Chemo Dosing - StockTitan
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO - The Manila Times
Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy - StockTitan
Assertio Holdings Inc (NASDAQ: ASRT): Blank Check On Growth? - Stocks Register
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewswire Inc.
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
HC Wainwright Forecasts Stronger Earnings for Assertio - MarketBeat
Assertio shares hold price target, buy rating on stable Indocin share By Investing.com - Investing.com Canada
Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Acquired by Empowered Funds LLC - Defense World
Assertio Holdings Q3 2024 Earnings Preview - MSN
Assertio stock gains amid Q3 earnings, clash with activist investor - MSN
Insider Buying: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Acquires $60,000.00 in Stock - MarketBeat
Assertio Holdings director Heather Mason buys $60,000 in shares By Investing.com - Investing.com Nigeria
Assertio Holdings director Heather Mason buys $60,000 in shares - Investing.com
Assertio Holdings CEO Brendan O'Grady buys $9,950 in common stock - Investing.com India
Spectrum Pharma Faces Senate Probe Call Over Alleged Rolvedon Data Fraud | ASRT Stock News - StockTitan
Assertio Holdings Inc (ASRT) Quarterly 10-Q Report - Quartz
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Call Transcript - Insider Monkey
Assertio: Q3 Earnings Snapshot - The Washington Post
Assertio Therapeutics’ Q3 2024 Earnings Overview - TipRanks
Assertio stock gains amid Q3 earnings, clash with activist investor (NASDAQ:ASRT) - Seeking Alpha
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Assertio Reports Third Quarter 2024 Financial Results - The Manila Times
Assertio Holdings Inc Stock (ASRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):